Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
AstraZeneca Loses Suit Seeking Block on Colorado Pharmacy Law
From Padcev to PF-08634404: Pfizer's Oncology Growth Push
Reviewing AstraZeneca (AZNCF) and Its Competitors - Zolmax
Reviewing AstraZeneca (AZNCF) & The Competition - Markets Daily
Astrazeneca FY2026 EPS Forecast Lowered by Erste Group Bank
Top Manufacturing Stocks To Keep An Eye On - August 30th - Stock Observer
Astrazeneca Plc $AZN Shares Sold by Davidson Investment Advisors
Thornburg Investment Management Inc. Acquires 32,775 Shares of Astrazeneca Plc $AZN - Daily Political
Davidson Investment Advisors Trims Position in Astrazeneca Plc $AZN - Daily Political
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Top Manufacturing Stocks To Research - August 28th - Zolmax
Head-To-Head Analysis: AstraZeneca (AZNCF) versus Its Rivals - Stock Observer
Tezspire Crossing to EoE? Astrazeneca, Amgen say phase III a win
BioCryst is profitable. Now it wants to buy more rare disease drugs
Genentech doubles down on ADC-resistance via $1B DualityBio pact
AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success
Glencore and GSK mine euros for popular deals
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AstraZeneca, Amgen's Tezspire Meets Co-Primary, Key Secondary Endpoints In Phase 3 EoE Trial
AstraZeneca drug succeeds in trial for swallowing disorder
Ageing, Innovation and AI: 10 Healthcare Stocks Positioned to Benefit | Financial Horse
AstraZeneca Vietnam upgrades logistics system to support growing operations
Analysts Set Astrazeneca Plc (NYSE:AZN) PT at $211.00 - Zolmax
AstraZeneca lands its largest ever euro deal
AstraZeneca prices €2.55bn euro bond sale across four tranches
Here Are Monday's Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino's Pizza, Fortune Brands, Golar LNG, Jersey Mike's Subs, Roku, and More
Towards a global collaborative approach to living guideline development in rheumatology
AstraZeneca's Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue?
AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?
AstraZeneca initiated with an Outperform at CICC
Astrazeneca Plc (NYSE:AZN) Given Consensus Rating of "Moderate Buy" by Analysts
Top Pharmaceutical Stocks To Research - August 20th - Daily Political
ET World Leaders Forum 2026: Boris Johnson thanks India for Covid vaccine, credits Brexit for UK rollout
AstraZeneca Loses Second Suit Against Medicare Drug Price Cuts
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript
Top Pharmaceutical Stocks To Research - August 20th - Markets Daily
7,500 Shares in Astrazeneca Plc $AZN Bought by Westport Asset Management Inc.
Alpro Group partners with AstraZeneca for kidney screening initiative
Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis
AstraZeneca (AZN) - Research Analysts' Weekly Ratings Changes - Zolmax
Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner | Morningstar
AstraZeneca (LSE:AZN) Reports Positive Phase III Lung Cancer Trial Results
Here's how much a £10,000 Stocks and Shares ISA could be worth by 2035
Can AstraZeneca (LSE:AZN) Still Be A Bargain After Mixed Trial News?
Mineralys (MLYS) Q2 2026 Earnings Call Transcript
Contrasting AstraZeneca (AZNCF) and Its Rivals - Stock Observer
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth | Morningstar
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch
Promising Manufacturing Stocks To Research - August 17th - Zolmax
AstraZeneca (AZN) Stock Edges Higher Despite Discontinuing Phase III Lung Cancer Study
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial | Morningstar
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
FTSE 100 set to snap six-day losing streak as miners gain
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review - Update | Morningstar
AstraZeneca Discontinues Phase 3 EVOLVE-Lung02 Trial Of Volrustomig In Non-small Cell Lung Cancer
Dow Jones Top Company Headlines at 5 AM ET: Alibaba to Sell Videogame Business for at Least $1.5 Billion | AstraZeneca ... | Morningstar
AstraZeneca (AZN) Stock Climbs on Promising Enhertu Cancer Trial Data
AstraZeneca ditches lung cancer treatment trial
HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial
AstraZeneca To Cease EVOLVE-Lung02 Phase III Trial Of Volrustomig + Chemotherapy In MNSCLC
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review | Morningstar
AstraZeneca lung cancer drug combination extends survival in trial
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig
S&CO Inc. Takes Position in Astrazeneca Plc $AZN
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Are Mega-Mergers Back?
Promising Manufacturing Stocks To Research - August 15th - Markets Daily
AstraZeneca (AZNCF) & Its Competitors Financial Review - Stock Observer
BMY: 2026 Pipeline And M&A Noise Will Not Mitigate Patent Cliff
Top Pharmaceutical Stocks Worth Watching - August 14th - Stock Observer
Global Drugmakers Investment: Global Drugmakers Invest $500 Billion to Enhance U.S. Manufacturing and Research, ETBrandEquity
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
AZN: Pipeline Strength And 2030 Revenue Ambition Will Drive Re Rating
Will AstraZeneca Have to Pay Medical Expenses for Woman Injured During COVID Vaccine Trial?
Leave no one behind: optimizing kidney protection in type 1 diabetes
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
Beyond the Scalpel: how the PROTEUS trial redefines the role of the radical prostatectomy
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn't Buy This Merger Talk
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
Lupin gets FDA nod for hyperkalemia drug
Astrazeneca Plc $AZN Shares Sold by NewEdge Advisors LLC
FY2026 EPS Estimates for Astrazeneca Cut by Erste Group Bank - Daily Political
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
AstraZeneca News
US Dollar Price Forecast 2026–2030: Can Fed Rate-Hike Bets Push DXY Above 100?
GBP/USD Forecast 2026–2030: Can Sterling Hold 1.35 as Fed–BoE Rate Bets Diverge?
Bitcoin Price Prediction 2026, 2027, 2030 & 2040: How High Can BTC Go?
USD/JPY Forecast 2026–2030: Will Another Move Above 160 Trigger Fresh Yen Intervention?
EUR/USD Forecast 2026–2030: Is 1.20 Still Within Reach After the Fed’s Hawkish Signal?
Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?
Gold Price Trend 2024-2026: From $2,000 to Record Highs, What Comes Next?
Latest news
Show more
Gold Price Today, September 1: Gold Holds Near $4,454 as Fed Rate-Hike Bets Limit Rebound
SanDisk Stock Jumps 5.5% as MSCI Inclusion and Mizuho Outlook Defy Market Sell-Off
Oil Price Today: Brent Holds Above $90 as Prolonged Iran Conflict Threatens Supply
Silver Price Today, September 1: Silver Holds Near $66.64 as Fed Rate-Hike Bets Limit Recovery
Shein IPO News Today: Shares Fall 10% in Hong Kong Debut as Valuation Slips Below $25 Billion
Broadcom Earnings Preview: Can AI Chip Growth Send AVGO Stock to Another Record?
